Dr. Ilka Wicke

Boehringer Ingelheim Venture Fund GmbH

In 2009 Ilka participated in the creation of the Boehringer Ingelheim Venture Fund as a strategic component of Boehringer Ingelheim to create an additional “window to external innovation“. Ilka joined the newly created Boehringer Ingelheim Venture Fund in 2010 as an investment manager and has since then been involved in several investments transactions of the fund. She serves as a board member for Promethera, Pcovery and Metabomed.

Ilka has obtained her PhD in organic chemistry from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches to stimulate antitumour responses. She joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. Thereafter, Ilka spent more than 13 years in the Corporate Licensing Division of Boehringer Ingelheim where she was responsible for the evaluation, negotiation and the management of several global licensing transactions.


+49 6132 775063